CLYM

Climb Bio (CLYM)

About Climb Bio (CLYM)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Details

Daily high

$4.96

Daily low

$4.50

Price at open

$4.59

52 Week High

$5.05

52 Week Low

$1.05

Market cap

330.7M

Dividend yield

0.00%

Volume

323,001

Avg. volume

2.7M

P/E ratio

-6.46

Climb Bio News